Global CD30 (TNFRSF8) Protein Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global CD30 (TNFRSF8) Protein Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor (TNFR) superfamily. CD30 can regulate proliferation of lymphocytes and may also play an important role in human immunodeficiency virus replication.
CD30 (TNFRSF8) Protein report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global CD30 (TNFRSF8) Protein market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from SDS-PAGE and ELISA are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for CD30 (TNFRSF8) Protein industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, CD30 (TNFRSF8) Protein key manufacturers include Sino Biological, Inc., Bio-Techne, Elabscience Biotechnology Inc., Abbexa, MyBiosource, Inc., OriGene Technologies, Inc., Prospec-Tany Technogene Ltd., KACTUS and G&P Biosciences, etc. Sino Biological, Inc., Bio-Techne, Elabscience Biotechnology Inc. are top 3 players and held % sales share in total in 2022.
CD30 (TNFRSF8) Protein can be divided into Purity Greater Than 85%, Purity Greater Than 90%, Purity Greater Than 95% and Purity Greater Than 97%, etc. Purity Greater Than 85% is the mainstream product in the market, accounting for % sales share globally in 2022.
CD30 (TNFRSF8) Protein is widely used in various fields, such as SDS-PAGE, ELISA and Others,, etc. SDS-PAGE provides greatest supports to the CD30 (TNFRSF8) Protein industry development. In 2022, global % sales of CD30 (TNFRSF8) Protein went into SDS-PAGE filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CD30 (TNFRSF8) Protein market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sino Biological, Inc.
Bio-Techne
Elabscience Biotechnology Inc.
Abbexa
MyBiosource, Inc.
OriGene Technologies, Inc.
Prospec-Tany Technogene Ltd.
KACTUS
G&P Biosciences
ACROBiosystems
Assay Genie
ZellBio GmbH
Segment by Type
Purity Greater Than 85%
Purity Greater Than 90%
Purity Greater Than 95%
Purity Greater Than 97%
Others
SDS-PAGE
ELISA
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the CD30 (TNFRSF8) Protein market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of CD30 (TNFRSF8) Protein, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the CD30 (TNFRSF8) Protein industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of CD30 (TNFRSF8) Protein in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, CD30 (TNFRSF8) Protein introduction, etc. CD30 (TNFRSF8) Protein Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of CD30 (TNFRSF8) Protein market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
CD30 (TNFRSF8) Protein report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global CD30 (TNFRSF8) Protein market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from SDS-PAGE and ELISA are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for CD30 (TNFRSF8) Protein industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, CD30 (TNFRSF8) Protein key manufacturers include Sino Biological, Inc., Bio-Techne, Elabscience Biotechnology Inc., Abbexa, MyBiosource, Inc., OriGene Technologies, Inc., Prospec-Tany Technogene Ltd., KACTUS and G&P Biosciences, etc. Sino Biological, Inc., Bio-Techne, Elabscience Biotechnology Inc. are top 3 players and held % sales share in total in 2022.
CD30 (TNFRSF8) Protein can be divided into Purity Greater Than 85%, Purity Greater Than 90%, Purity Greater Than 95% and Purity Greater Than 97%, etc. Purity Greater Than 85% is the mainstream product in the market, accounting for % sales share globally in 2022.
CD30 (TNFRSF8) Protein is widely used in various fields, such as SDS-PAGE, ELISA and Others,, etc. SDS-PAGE provides greatest supports to the CD30 (TNFRSF8) Protein industry development. In 2022, global % sales of CD30 (TNFRSF8) Protein went into SDS-PAGE filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CD30 (TNFRSF8) Protein market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sino Biological, Inc.
Bio-Techne
Elabscience Biotechnology Inc.
Abbexa
MyBiosource, Inc.
OriGene Technologies, Inc.
Prospec-Tany Technogene Ltd.
KACTUS
G&P Biosciences
ACROBiosystems
Assay Genie
ZellBio GmbH
Segment by Type
Purity Greater Than 85%
Purity Greater Than 90%
Purity Greater Than 95%
Purity Greater Than 97%
Others
Segment by Application
SDS-PAGE
ELISA
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the CD30 (TNFRSF8) Protein market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of CD30 (TNFRSF8) Protein, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the CD30 (TNFRSF8) Protein industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of CD30 (TNFRSF8) Protein in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, CD30 (TNFRSF8) Protein introduction, etc. CD30 (TNFRSF8) Protein Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of CD30 (TNFRSF8) Protein market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices